Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it has commenced an underwritten public offering of 7,000,000 shares of its common stock. All of these shares are being sold by Alnylam.
J.P. Morgan Securities LLC is acting as sole book-running manager for the proposed offering. Alnylam intends to grant the underwriter a 30-day option to purchase up to an additional 1,050,000 shares to cover overallotments, if any. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the final size or terms of the offering.
A review of clinical features, diagnosis, and management of Mpox